The National Health Surveillance Agency (Anvisa) has determined the prohibition of marketing products containing tirzepatide and retatrutide that are advertised on Brazilian websites without possessing sanitary registration. This decision implies the seizure of the items and restricts various related activities, including manufacturing, importation, distribution, and advertising.
The guidelines were formally published in the Official Gazette of the Union (DOU) this Wednesday, the 14th, and cover other medicines and articles sold online that are not properly regulated by the agency.
Tirzepatide is the active component of the drug Mounjaro, used for both type 2 diabetes management and weight control. Its action occurs through the GIP and GLP-1 hormone receptors, which are linked to blood glucose modulation and appetite regulation.
Retatrutide, on the other hand, acts on three distinct hormonal pathways: GLP-1, GIP, and the glucagon receptor. Although under investigation, this substance does not yet have approval to be used or sold in any nation.
Anvisa located illegal products on three online platforms. According to the resolution, products supplied by Oxygen KWP Pharma Brasil were produced by an unknown company. Regarding ZPHC Store, the agency clarified that the tirzepatide items are not equivalent to the drug registered in Brazil, and that the retatrutide products lack authorization for national commercialization.
The ban extends to individuals, corporations, and media outlets that promote or sell the investigated products. Furthermore, the measure covers items advertised on Zyntrashop, where the agency could not confirm the origin or identify the manufacturers, although the advertisements displayed prices, purchase options, and usage details.
Another affected entity was Cris Barden Naturopatia Ltda. The resolution requires the seizure of products such as the Detox – Parasitize – De-inflammatory – Detoxify kits, available in children's (ages 1 to 5) and adult versions, as well as the Coconut Shell Powdered Charcoal Kit.
Anvisa pointed out that these items were being advertised without any sanitary registration, notification, or registry, and that the company does not hold permission from the agency to manufacture pharmaceuticals. The imposed restrictions prohibit the stocking, sale, circulation, and advertising of these articles, reserving imports made by individuals for personal use.